The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no ...

Combination treatment with entinostat and nivolumab results in durable responses in a small subset of patients with advanced ...

Adjuvant Opdivo showed a significant improvement in overall survival and disease-free survival for patients with high-risk ...

Management of advanced renal cell carcinoma remains a persistent clinical challenge with high morbidity and mortality for a large proportion of patients. Until recently, available medical ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 inhibitor–exposed melanoma. A biologics license application (BLA) seeking the accelerated ...

The FDA notified EXEL that its sNDA seeking label expansion of cabozantinib will be discussed at an ODAC meeting in March 2025.

Discover which therapies are expected to grab the PD/L-1 Market Share @ PD/L-1 Treatment Market Size ...

Secondary endpoints included overall survival, radiographic response rate and safety. In the US, Cabometyx tablets are approved as monotherapy for the treatment of patients with advanced renal cell ...

Because the V Foundation has an endowment to cover administrative expenses, 100% of direct donations are awarded to cancer research. The V team is committed to accelerating Victory Over Cancer ...